Price Chart

Profile

Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.
URL http://www.enlivex.com
Investor Relations URL https://enlivex.com/investor-relations/
HQ State/Province Tel Aviv
Sector Health Care
Industry Biotechnology
Next Earnings Release N/A
Last Earnings Release Nov. 18, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.
URL http://www.enlivex.com
Investor Relations URL https://enlivex.com/investor-relations/
HQ State/Province Tel Aviv
Sector Health Care
Industry Biotechnology
Next Earnings Release N/A
Last Earnings Release Nov. 18, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A